Medication info
Kosalatan Plus Tablet

Kosalatan Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Kolon Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200606825 · Notified 2006.08.11

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when monotherapy does not produce the expected effect. 1. Replacement therapy: The combination of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or greater. Use of a loop diuretic rather than a thiazide is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. Patients with hepatic impairment This medicine cannot provide the initial dose of losartan potassium, 25 mg, for patients with hepatic impairment who require dose adjustment; therefore, use in these patients is not recommended.
Child dose
Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Kolon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for patients with hypertension who have difficulty controlling blood pressure with monotherapy. Since hypertension can affect cardiovascular health, proper blood pressure control is important. This medicine helps effectively lower blood pressure and improve the patient's health.

How to take

Adult dose

Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when monotherapy does not produce the expected effect. 1. Replacement therapy: The combination of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or greater. Use of a loop diuretic rather than a thiazide is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. Patients with hepatic impairment This medicine cannot provide the initial dose of losartan potassium, 25 mg, for patients with hepatic impairment who require dose adjustment; therefore, use in these patients is not recommended.

Child dose

Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. It should not be administered to patients with allergic reactions to this medication or specific kidney diseases, liver dysfunction, or electrolyte imbalances. Patients with certain health conditions such as hypotension, kidney issues, liver disease, diabetes, gout, and the elderly should be particularly cautious when using this medication and should follow a doctor's instructions. Since this medication lowers blood pressure, dizziness or drowsiness may occur when first taken, so caution is necessary when driving or operating machinery. While taking this medication, electrolytes levels and kidney function in the blood should be regularly checked to ensure there are no abnormalities. This medication may interact with other drugs, so it's important to consult with a doctor if taking potassium supplements, certain diuretics, or non-steroidal anti-inflammatory drugs. It can increase the sensitivity of the skin to sunlight, which may raise the risk of skin cancer, so sun exposure should be limited, and any changes in the skin should be reported to a physician immediately. In case of overdose, serious symptoms such as hypotension or cardiac arrhythmias may occur, so the prescribed dosage must be adhered to; if unusual symptoms arise, immediate consultation with medical staff is required. This medication is recommended to not be used in children and adolescents due to insufficient experience, and caution is needed when administered to breastfeeding women. Finally, this medication should be stored out of reach of children and kept in its original container to prevent misuse or quality deterioration.

Side effects

  • Craniosynostosis
  • Anuria
  • Hypotension
  • Renal failure
  • Death
  • Abdominal pain
  • Edema
  • Palpitations
  • Low back pain
  • Dizziness
Show 130 more
  • Cough
  • Sinusitis
  • Upper respiratory tract infection
  • Rash
  • Angioedema
  • Skin peeling phenomenon
  • Hemolysis
  • Chest pain
  • Facial swelling
  • Fever
  • Orthostatic hypotension
  • Syncope
  • Angina
  • Arrhythmia
  • Cerebrovascular accident
  • Myocardial infarction
  • Secondary atrioventricular block
  • Loss of appetite
  • Constipation
  • Toothache
  • Dry mouth
  • Dyspepsia
  • Flatulence
  • Gastritis
  • Vomiting
  • Fatigue
  • Anemia
  • Gout
  • Arm pain
  • Joint pain
  • Arthritis
  • Fibromyalgia
  • Hip pain
  • Joint swelling
  • Knee pain
  • Limb pain
  • Muscle cramp
  • Muscle weakness
  • Musculoskeletal pain
  • Myalgia
  • Shoulder pain
  • Muscle rigidity
  • Anxiety
  • Anxiety disorder
  • Ataxia
  • Confusion
  • Depression
  • Nightmares
  • Sensory impairment
  • Insomnia
  • Reduced libido
  • Memory impairment
  • Migraine
  • Hyperesthesia
  • Panic disorder
  • Sensory disturbance
  • Peripheral neuropathy
  • Sleep disorder
  • Drowsiness
  • Tremor
  • Dyspnea
  • Epistaxis
  • Nasal congestion
  • Pharyngeal discomfort
  • Respiratory congestion
  • Rhinitis
  • Venous sinus obstruction
  • Chest discomfort
  • Alopecia
  • Dermatitis
  • Skin dryness
  • Purpura
  • Erythema
  • Flush
  • Photosensitivity reaction
  • Pruritus
  • Sweating
  • Urticaria
  • Blurred vision
  • Ocular pain
  • Burning sensation
  • Conjunctivitis
  • Visual impairment
  • Taste disturbance
  • Tinnitus
  • Erectile dysfunction
  • Nocturia
  • Polyuria
  • Urinary tract infection
  • Weakness
  • Pancreatitis
  • Jaundice
  • Sialadenitis
  • Spasm
  • Gastrointestinal irritation
  • Aplastic anemia
  • Agranulocytosis
  • Leukopenia
  • Thrombocytopenia
  • Purpura
  • Necrotizing vasculitis
  • Pneumonia
  • Pulmonary edema
  • Acute respiratory distress syndrome
  • Hyperglycemia
  • Diabetes
  • Muscle spasm
  • Agitation
  • Renal dysfunction
  • Interstitial nephritis
  • Skin and mucosal syndrome
  • Erythema multiforme
  • Toxic epidermal necrolysis
  • Transient blurred vision
  • Xanthopsia
  • Acute myopia
  • Acute closed-angle glaucoma
  • Choroidal exudate
  • Hypotension
  • Tachycardia
  • Angioedema
  • Vasculitis
  • Anaphylactic reaction
  • Hepatitis
  • Intestinal vascular edema
  • Dry cough
  • Erythema
  • Hyperkalemia
  • Hyponatremia
  • Rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container that can block light and kept in a cool place between 15 to 30 degrees Celsius. This way, the efficacy of the medication can be maintained for a long time.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.